<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986323</url>
  </required_header>
  <id_info>
    <org_study_id>Air 3-03</org_study_id>
    <nct_id>NCT00986323</nct_id>
    <nct_alias>NCT00986388</nct_alias>
    <nct_alias>NCT00986622</nct_alias>
    <nct_alias>NCT00986726</nct_alias>
    <nct_alias>NCT00986934</nct_alias>
  </id_info>
  <brief_title>Efficacy Study of Temperature Controlled Laminar Airflow (TLA)-Treatment in Perennial Allergic Asthma</brief_title>
  <acronym>4A</acronym>
  <official_title>Airsonett Airshower in Allergic Asthma a Double-blind Randomized Multi-centre Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Airsonett AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Commitum AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Croel AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Airsonett AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether nocturnal environmental control with
      Temperature controlled Laminar Airflow (TLA) is effective as add on treatment in patients
      with perennial allergic asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exposure to inhaled allergens is a pathogenetic factor in allergic asthma. However, physical,
      chemical and combined methods aiming to reduce airborne allergen levels have shown little or
      no effect in reducing asthma symptoms in people who are sensitive to perennial allergens.Aims
      and objectives: This study aims to investigate treatment with Temperature controled Laminar
      Airflow (TLA) with a very low particle concentration directed to the breathing zone in
      subjects with allergic asthma during night sleep. The hypothesis is that the decreased
      allergen exposure during the night will have an effect on quality of life and bronchial
      inflammation.

      Method: This is a multicentre, double blind, randomized 52 week parallel trial comparing
      active TLA treatment with Placebo. For ethical reasons the randomization is 2 to 1 for active
      and placebo treatment, respectively. A 2 weeks run-in period is inserted between inclusion
      and randomization, during which the patient shall get familiar with the use of the patient
      asthma diary and to adhere to the requirements of the study participation. First 12 weeks an
      unchanged maintenance medication will be kept and week 13-52 medication will be modified to
      obtain asthma control according to international guidelines (GINA). After inclusion, run-in,
      randomization and baseline measurements active/placebo treatment with AA will be implemented
      over 52 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>miniAQLQ (Mini Asthma Quality of Life Questionnaire, Appendix 1) and the corresponding paediatric PAQLQ score.</measure>
    <time_frame>Week -2, 0, 4, 12, 24, 36 and 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FENO (Nitric Oxide in Exhaled Air)</measure>
    <time_frame>Week -2, 0, 4, 12, 24, 36 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function assessed by forced expiratory volume (FEV1), PEF (Expiratory peak flow) and FEF50 (Predicted Forced Expiratory Flow Rate at 50 Percent of Vital Capacity)</measure>
    <time_frame>Week -2, 0, 4, 12, 24, 36 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinitis symptoms assessed by questionnaire</measure>
    <time_frame>Week 0 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAST value and eosinophil count.</measure>
    <time_frame>Week 0 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Test (ACT).</measure>
    <time_frame>Week -2, 0, 12, 24, 36 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource consumption</measure>
    <time_frame>Week 0, 4, 12, 24, 36 and 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">312</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Temeperature controlled Laminar Airflow</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active treatment with Temperature controlled Laminar Airflow (TLA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo TLA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo TLA treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Temperature controlled Laminar Airflow (TLA)</intervention_name>
    <description>Nocturnal environmental control with Temperature controlled Laminar Airflow (TLA).</description>
    <arm_group_label>Temeperature controlled Laminar Airflow</arm_group_label>
    <other_name>Protexo</other_name>
    <other_name>TLA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo TLA</intervention_name>
    <description>Placebo TLA (without filtration and TLA function)</description>
    <arm_group_label>Placebo TLA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consent to participate voluntarily. Willing and able to comply with the study specific
             procedures. Signed Informed Consent prior to any study procedure.

          -  Perennial allergic asthma, male and female, age 7 through 70 years, at time of
             randomization.

          -  A miniAQLQ/PAQLQ score of ≤ 5.5.

          -  Sensitive to pet allergen and/or house dust mites as demonstrated by changed to RAST
             0.70 or positive skin prick test (wheal reaction similar to histamine control).

          -  Daily maintenance dose of at least ICS ≥200µg/day of budesonide or ≥100µg/day of
             fluticasone since at least 6 months

          -  Features of partly controlled asthma according to GINA

        Exclusion Criteria:

          -  Current smoker (Non-smoker is defined as abstinent since &gt; 1 year). Children:
             Parents'indoor smoking.

          -  Participation in another allergen avoidance program

          -  Participation in drug trial the preceding 3 months

          -  Multiple chemical sensitivity (e.g. paint, petrol, perfumes) as primary etiology

          -  Allergen injection or sublingual treatment in the preceding 2 years

          -  ICS ≥1200µg/day of budesonide or 1000µg/day of fluticasone

          -  Significant cardiovascular disease

          -  Participation in the present trial of a family member within the same household

        Other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olof Zetterström, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Linkoeping</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku Allergy Centre</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhr University of Bochum</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Wesel</name>
      <address>
        <city>Wesel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ullevaal University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ängelholm Hospital</name>
      <address>
        <city>Angelholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital, Sweden</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonkoping County Hospital</name>
      <address>
        <city>Jonkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Council of Värmland</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Linkoeping</name>
      <address>
        <city>Linkoeping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S:t Görans Hospital, Sweden</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stockholm South General Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2009</study_first_submitted>
  <study_first_submitted_qc>September 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2009</study_first_posted>
  <last_update_submitted>November 8, 2010</last_update_submitted>
  <last_update_submitted_qc>November 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Chris Anderson, Head of activity</name_title>
    <organization>University Hospital, Linkoeping, Sweden</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Temperature controlled Laminar Airflow</keyword>
  <keyword>TLA</keyword>
  <keyword>Perennial allergy</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Environmental control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

